« Return to News | CROs/Service Providers

Premier Research expands in Salt Lake City and Phoenix

Thursday, February 23, 2012 02:39 PM

CRO Premier Research Group is opening state-of-the-art clinical research facilities in Phoenix, Ariz., and Salt Lake City, Utah, increasing its testing facilities capacity by 50%.
 
“We are excited to be expanding our existing clinical research facilities to accommodate more phase I and outpatient studies,” stated Michael Kuss, vice president, analgesia, Premier Research.

The new facilities give Premier Research the capability to reach and house more study volunteers, as well as successfully conduct phase II and III chronic pain, migraine, dysmenorrhea, vaccine, obesity and other models at all of its sites, according to Kuss.
 
Premier Research has been in the Phoenix market since 1993 and in Salt Lake City since 1999.

In addition to its CRO offerings, Premier Research owns and operates a network of clinical research centers offering clinical site services from phase I proof-of-concept trials to phase IV post-marketing trials, primarily in healthy normal volunteers, acute and chronic pain, rheumatology and neuroscience.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.